Efficacy and safety of elranatamab in Japanese patients with relapsed/refractory multiple myeloma (RRMM): a pooled analysis from the MagnetisMM studies

被引：0
|
作者：
Ishida, Tadao [1 ]
Yokoyama, Hisayuki [2 ]
Suzuki, Kenshi [1 ]
Ito, Satoshi [3 ]
Nagai, Yuya [4 ]
Handa, Hiroshi [5 ]
Ito, Shigeki [6 ]
Kamei, Yoichi [7 ]
Nakamura, Masatoshi [7 ]
Viqueira, Andrea [8 ]
White, Jane Liang [9 ]
Take, Kazumi [9 ]
Moribe, Toyoki [10 ]
Iida, Shinsuke [11 ]
机构：
[1] Japanese Red Cross Med Ctr, Tokyo, Japan
[2] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan
[3] Yamagata Univ Hosp, Yamagata, Japan
[4] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan
[5] Gunma Univ, Grad Sch Med, Maebashi, Gumma, Japan
[6] Iwate Med Univ, Sch Med, Yahaba, Iwate, Japan
[7] Pfizer R&D Japan GK, Tokyo, Japan
[8] Pfizer SLU, Madrid, Spain
[9] Pfizer Inc, Groton, CT USA
[10] Pfizer Japan Inc, Tokyo, Japan
[11] Nagoya City Univ, Inst Med & Pharmaceut Sci, Nagoya, Aichi, Japan
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-274
引用
收藏
页码：S186 / S187
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnetismm Studies
    Varshavsky-Yanovsky, Asya
    Jethava, Yogesh
    Stevens, Don A.
    Nooka, Ajay K.
    Stiff, Patrick J.
    Perez-Cruz, Isabel
    Leip, Eric
    Lesokhin, Alexander
    BLOOD, 2023, 142
  • [2] Elranatamab Exposure-Efficacy Analysis in Patients with Relapsed or Refractory Multiple Myeloma: Insights from Pooled Magnetismm Studies
    Lon, Hoi Kei
    Hibma, Jennifer
    Williams, Jason
    Wang, Diane
    Gifondorwa, David
    Ma, Wei An
    King, Lindsay
    Conte, Umberto
    Czibere, Akos
    Elmeliegy, Mohamed
    BLOOD, 2023, 142
  • [3] Efficacy and Safety of Elranatamab by Age and Frailty in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Subgroup Analysis From MagnetisMM-3
    Raje, Noopur
    Leleu, Xavier
    Lesokhin, Alexander
    Mohty, Mohamad
    Nooka, Ajay K.
    Leip, Eric
    Conte, Umberto
    Viqueira, Andrea
    Manier, Salomon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S497 - S497
  • [4] Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)-Directed Therapies: Pooled Analysis From MagnetisMM Studies
    Nooka, Ajay K.
    Lesokhin, Alexander M.
    Mohty, Mohamad
    Niesvizky, Ruben
    Maisel, Christopher
    Arnulf, Bertrand
    Larson, Sarah M.
    Varshavsky-Yanovsky, Asya Nina
    Leleu, Xavier
    Karlin, Lionel
    Vesole, David H.
    Bahlis, Nizar J.
    Fernandez de Larrea, Carlos
    Raje, Noopur
    Leip, Eric
    Conte, Umberto
    Elmeliegy, Mohamed
    Viqueira, Andrea
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S496 - S497
  • [5] Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3
    Raab, M. S.
    Haenel, M.
    Raje, N.
    Leleu, X.
    Lesokhin, A.
    Mohty, M.
    Nooka, A. K.
    Leip, E.
    Conte, U.
    Viqueira, A.
    Manier, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 80 - 81
  • [6] Elranatamab exposure-safety analysis in patients with relapsed/refractory multiple myeloma: analysis from MagnetisMM studies
    Soltantabar, Pooneh
    Irby, Donald
    Hibma, Jennifer
    Wang, Diane
    Williams, Jason
    Czibere, Akos
    Viqueira, Andrea
    Hickman, Anne
    Elmeliegy, Mohamed
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S211 - S212
  • [7] Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3
    Larson, Sarah Marie
    Bahlis, Nizar J.
    Maisel, Christopher
    Karlin, Lionel
    Yanovsky, Asya Varshavsky
    Leip, Eric
    Sullivan, Sharon T.
    Viqueira, Andrea
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
    Nooka, Ajay K.
    Lesokhin, Alexander M.
    Mohty, Mohamad
    Niesvizky, Ruben
    Maisel, Christopher
    Arnulf, Bertrand
    Larson, Sarah Marie
    Yanovsky, Asya Varshavsky
    Leleu, Xavier P.
    Karlin, Lionel
    Vesole, David H.
    Bahlis, Nizar J.
    de Larrea, Carlos Fernandez
    Raje, Noopur S.
    Leip, Eric
    Conte, Umberto
    Elmeliegy, Mohamed
    Viqueira, Andrea
    Manier, Salomon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Pooled Analysis of MagnetisMM Studies: Efficacy and Safety of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Previously Exposed to B-cell Maturation Antigen (BCMA)-Directed Therapies
    Ajay, Nooka K.
    Alexander, Lesokhin M.
    Mahamad, Mohty
    Ruben, Niesvizky
    Christopher, Maisel
    Bertrand, Arnulf
    Sarah, Larson M.
    Nina, Asya Varshavsky-Yanovsky
    Xavier, Leleu
    Lionel, Karlin
    David, Vesole H.
    Nizar, Bahlis J.
    de Larrea Carlos, Fernandez
    Noopur, Raje
    Eric, Leip
    Umbarto, Conte
    Mohamed, Elmeliegy
    Andrea, Viqueira
    Saloman, Manier
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S27 - S28
  • [10] Efficacy and safety of elranatamab in pts with relapsed/ refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies
    Raab, M. S.
    Hanel, M.
    Nooka, A. K.
    Lesokhin, A. M.
    Mohty, M.
    Niesvizky, R.
    Maisel, C.
    Arnulf, B.
    Larson, S. M.
    Varshavsky-Yanovsky, A. N.
    Leleu, X.
    Karlin, L.
    Vesole, D. H.
    Bahlis, N. J.
    de larrea, Fernandez C.
    Raje, N.
    Leip, E.
    Conte, U.
    Elmeliegy, M.
    Viqueira, A.
    Manier, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 232 - 232
12345